[{"id":"df928720-03da-42b3-a83f-dd24e4e18afa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05695898","created_at":"2023-01-25T18:00:06.300Z","updated_at":"2024-07-02T16:35:12.998Z","phase":"Phase 1","brief_title":"XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy","source_id_and_acronym":"NCT05695898","lead_sponsor":"University of California, San Francisco","biomarkers":" PD-L1 • BRAF • LAG3","pipe":"","alterations":" ","tags":["PD-L1 • BRAF • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bavunalimab (XmAb22841) • izuralimab (XmAb23104)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 02/28/2023","start_date":" 02/28/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-25"},{"id":"23090ad0-12d2-47eb-b8d8-dc2a255c3aad","acronym":"DUET-4","url":"https://clinicaltrials.gov/study/NCT03849469","created_at":"2021-01-18T18:59:59.498Z","updated_at":"2024-07-02T16:35:51.893Z","phase":"Phase 1","brief_title":"A Study of XmAb®22841 Monotherapy \u0026 in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors","source_id_and_acronym":"NCT03849469 - DUET-4","lead_sponsor":"Xencor, Inc.","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • bavunalimab (XmAb22841)"],"overall_status":"Completed","enrollment":" Enrollment 78","initiation":"Initiation: 05/29/2019","start_date":" 05/29/2019","primary_txt":" Primary completion: 02/16/2023","primary_completion_date":" 02/16/2023","study_txt":" Completion: 02/16/2023","study_completion_date":" 02/16/2023","last_update_posted":"2023-03-30"}]